pepinemab
mAbexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 12, 2018 (NCT03320330)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Semaphorin-4DINHIBITOR
Semaphorin-4D inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297884 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05378464 | Phase 1 | May 31, 2022 | University of South Florida, Vaccinex Inc. |
| NCT05102721 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | University of Rochester |
| NCT04815720 | Phase 1/Phase 2 (Phase 2) | Aug 9, 2021 | Merck, Vaccinex Inc. |
| NCT04381468 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2020 | Alzheimer's Association, Alzheimer’s Drug Discovery Foundation, Vaccinex Inc. |
| NCT03320330 | Phase 1/Phase 2 (Phase 2) | Jan 12, 2018 | National Cancer Institute (NCI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaccinex Inc. | For profit | 3 | 2 | 2 | 2020 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Alzheimer’s Drug Discovery Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2018 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2022 |
7 organizations
Page 1 / 1